NYSE
EW

Edwards Lifesciences Corp

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

Edwards Lifesciences Corp Stock Price

Vitals

Today's Low:
$73.06
Today's High:
$74.945
Open Price:
$74.47
52W Low:
$67.13
52W High:
$107.92
Prev. Close:
$74.87
Volume:
3237409

Company Statistics

Market Cap.:
$52.10 billion
Book Value:
9.865
Revenue TTM:
$5.50 billion
Operating Margin TTM:
32.39%
Gross Profit TTM:
$4.30 billion
Profit Margin:
27.07%
Return on Assets TTM:
13.05%
Return on Equity TTM:
25.01%

Company Profile

Edwards Lifesciences Corp had its IPO on 2000-03-27 under the ticker symbol EW.

The company operates in the Healthcare sector and Medical Devices industry. Edwards Lifesciences Corp has a staff strength of 17,300 employees.

Stock update

Shares of Edwards Lifesciences Corp opened at $74.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $73.06 - $74.95, and closed at $73.37.

This is a -2% slip from the previous day's closing price.

A total volume of 3,237,409 shares were traded at the close of the day’s session.

In the last one week, shares of Edwards Lifesciences Corp have slipped by -3.94%.

Edwards Lifesciences Corp's Key Ratios

Edwards Lifesciences Corp has a market cap of $52.10 billion, indicating a price to book ratio of 7.5391 and a price to sales ratio of 8.4778.

In the last 12-months Edwards Lifesciences Corp’s revenue was $5.50 billion with a gross profit of $4.30 billion and an EBITDA of $1.92 billion. The EBITDA ratio measures Edwards Lifesciences Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Edwards Lifesciences Corp’s operating margin was 32.39% while its return on assets stood at 13.05% with a return of equity of 25.01%.

In Q1, Edwards Lifesciences Corp’s quarterly earnings growth was a negative -5.1% while revenue growth was a positive 8.8%.

Edwards Lifesciences Corp’s PE and PEG Ratio

Forward PE
30.1205
Trailing PE
35.2213
PEG
3.0653

Its diluted EPS in the last 12-months stands at $2.44 per share while it has a forward price to earnings multiple of 30.1205 and a PEG multiple of 3.0653. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Edwards Lifesciences Corp’s profitability.

Edwards Lifesciences Corp stock is trading at a EV to sales ratio of 8.5433 and a EV to EBITDA ratio of 23.1882. Its price to sales ratio in the trailing 12-months stood at 8.4778.

Edwards Lifesciences Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$8.65 billion
Total Liabilities
$1.08 billion
Operating Cash Flow
$500000.00
Capital Expenditure
$61.50 million
Dividend Payout Ratio
0%

Edwards Lifesciences Corp ended 2024 with $8.65 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $8.65 billion while shareholder equity stood at $5.98 billion.

Edwards Lifesciences Corp ended 2024 with $0 in deferred long-term liabilities, $1.08 billion in other current liabilities, 647100000.00 in common stock, $7.93 billion in retained earnings and $1.31 billion in goodwill. Its cash balance stood at $872.50 million and cash and short-term investments were $1.25 billion. The company’s total short-term debt was $25,100,000 while long-term debt stood at $596.50 million.

Edwards Lifesciences Corp’s total current assets stands at $3.26 billion while long-term investments were $1.07 billion and short-term investments were $381.70 million. Its net receivables were $779.30 million compared to accounts payable of $180.80 million and inventory worth $914.30 million.

In 2024, Edwards Lifesciences Corp's operating cash flow was $500000.00 while its capital expenditure stood at $61.50 million.

Comparatively, Edwards Lifesciences Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$73.37
52-Week High
$107.92
52-Week Low
$67.13
Analyst Target Price
$94

Edwards Lifesciences Corp stock is currently trading at $73.37 per share. It touched a 52-week high of $107.92 and a 52-week low of $107.92. Analysts tracking the stock have a 12-month average target price of $94.

Its 50-day moving average was $82.71 and 200-day moving average was $81.69 The short ratio stood at 3.66 indicating a short percent outstanding of 0%.

Around 83.8% of the company’s stock are held by insiders while 8723.4% are held by institutions.

Frequently Asked Questions About Edwards Lifesciences Corp

The stock symbol (also called stock or share ticker) of Edwards Lifesciences Corp is EW

The IPO of Edwards Lifesciences Corp took place on 2000-03-27

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$369.55
-12.45
-3.26%
$0.6
0.02
+2.92%
$14562.65
-279.2
-1.88%
$29.57
0.16
+0.54%
$121.63
-1.48
-1.2%
$8.8
0.11
+1.27%
$0.73
0
+0.01%
SRF Limited (503806)
$2374.2
-62.3
-2.56%
$31.21
0.24
+0.77%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Address

One Edwards Way, Irvine, CA, United States, 92614